Senate Democrats have unveiled legislation that would require the Trump administration to disclose the terms of what they call “sweetheart” deals signed with more than a dozen of the largest pharmaceutical companies.
Introduced by Sen. Ron Wyden, the ranking member of the Senate Finance Committee, and 17 additional Democratic senators, the